- Home
- ORKA vs AMAL Comparison
ORKA vs AMAL Comparison
Compare ORKA & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORKA | AMAL |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 1.5B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ORKA | AMAL |
|---|---|---|
| Price | $92.38 | $47.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $92.50 | $36.00 |
| AVG Volume (30 Days) | ★ 755.8K | 152.5K |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.99 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.18 |
| Revenue Next Year | N/A | $6.55 |
| P/E Ratio | ★ N/A | $24.04 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.67 | $25.13 |
| 52 Week High | $115.52 | $51.59 |
Technical Indicators
Market Signals| Indicator | ORKA | AMAL |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 46.51 |
| Support Level | $83.25 | $47.06 |
| Resistance Level | $95.02 | $51.25 |
| Average True Range (ATR) | 5.20 | 0.89 |
| MACD | -1.39 | -0.15 |
| Stochastic Oscillator | 24.40 | 35.99 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.